X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA STRIDES PHARMA SCIENCE PLETHICO PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x -1.1 52.2 - View Chart
P/BV x 0.0 1.1 1.5% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 PLETHICO PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
STRIDES PHARMA SCIENCE
Mar-18
PLETHICO PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3951,147 34.4%   
Low Rs31642 4.9%   
Sales per share (Unadj.) Rs604.4317.2 190.5%  
Earnings per share (Unadj.) Rs32.57.8 414.0%  
Cash flow per share (Unadj.) Rs51.325.1 204.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs473.6274.3 172.7%  
Shares outstanding (eoy) m34.0889.50 38.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.42.8 12.5%   
Avg P/E ratio x6.6114.0 5.8%  
P/CF ratio (eoy) x4.235.7 11.6%  
Price / Book Value ratio x0.53.3 13.8%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m7,26280,058 9.1%   
No. of employees `000NA2.5 0.0%   
Total wages/salary Rs m1,5964,341 36.8%   
Avg. sales/employee Rs ThNM11,325.8-  
Avg. wages/employee Rs ThNM1,731.4-  
Avg. net profit/employee Rs ThNM280.1-  
INCOME DATA
Net Sales Rs m20,59828,394 72.5%  
Other income Rs m386941 41.1%   
Total revenues Rs m20,98429,334 71.5%   
Gross profit Rs m2,8183,965 71.1%  
Depreciation Rs m6421,540 41.7%   
Interest Rs m1,5931,962 81.2%   
Profit before tax Rs m9691,403 69.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m-13897 -142.2%   
Profit after tax Rs m1,107702 157.7%  
Gross profit margin %13.714.0 97.9%  
Effective tax rate %-14.36.9 -206.1%   
Net profit margin %5.42.5 217.3%  
BALANCE SHEET DATA
Current assets Rs m18,87724,836 76.0%   
Current liabilities Rs m11,89618,993 62.6%   
Net working cap to sales %33.920.6 164.7%  
Current ratio x1.61.3 121.3%  
Inventory Days Days3671 50.6%  
Debtors Days Days198113 174.4%  
Net fixed assets Rs m9,86134,289 28.8%   
Share capital Rs m341895 38.1%   
"Free" reserves Rs m12,33123,651 52.1%   
Net worth Rs m16,13924,546 65.7%   
Long term debt Rs m4,70615,513 30.3%   
Total assets Rs m33,14665,437 50.7%  
Interest coverage x1.61.7 93.8%   
Debt to equity ratio x0.30.6 46.1%  
Sales to assets ratio x0.60.4 143.2%   
Return on assets %8.14.1 200.1%  
Return on equity %6.92.9 239.8%  
Return on capital %12.36.9 178.3%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40215,697 28.0%   
Fx outflow Rs m3,184735 432.9%   
Net fx Rs m1,21914,962 8.1%   
CASH FLOW
From Operations Rs m2,4371,871 130.3%  
From Investments Rs m-6,2655,826 -107.5%  
From Financial Activity Rs m2,490-10,157 -24.5%  
Net Cashflow Rs m-1,337-2,615 51.1%  

Share Holding

Indian Promoters % 82.7 27.7 298.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 37.8 11.4%  
FIIs % 5.5 8.6 64.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 25.9 29.0%  
Shareholders   10,665 56,241 19.0%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare PLETHICO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES SHASUN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Oct 1, 2018 | Updated on Oct 1, 2018

Here's an analysis of the annual report of STRIDES SHASUN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES SHASUN LTD. Also includes updates on the valuation of STRIDES SHASUN LTD.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS